Related Experiment Video
Updated: Aug 13, 2025

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis
Published on: July 18, 2017
Corticosteroids to prevent renal scarring in children with pyelonephritis: a systematic review and meta-analysis
Johanna Jääskeläinen1, Marjo Renko2,3, Ilari Kuitunen2,4
1Institute of Clinical Medicine and Department of Pediatrics, University of Eastern Finland, Yliopistonranta 2, 70211, Kuopio, Finland. johajaa@student.uef.fi.
Insights
Corticosteroid treatment, when combined with antibiotics, may prevent kidney scarring in children with acute pyelonephritis. Further research is needed to confirm effectiveness and safety.
Area of Science:
- Pediatric Nephrology
- Infectious Diseases
- Pharmacology
Background:
- Acute pyelonephritis is a common pediatric infection.
- It can lead to significant renal scarring.
- Preventing renal scarring is crucial for long-term kidney health in children.
Approach:
- Systematic review and meta-analysis of randomized controlled trials.
- Searched major databases (PubMed, Scopus, Cochrane, Web of Science).
- Included studies comparing corticosteroid + antibiotics vs. antibiotics alone or with placebo.
Key Points:
- Moderate quality evidence suggests corticosteroids reduce renal scarring risk (RR 0.65, NNT 8).
- Renal scarring occurred in 14.1% with corticosteroids vs. 27.3% in controls.
- Risk of bias was a concern in four of five included studies.
Conclusions:
- Adjuvant corticosteroid therapy shows potential in preventing renal scarring in pediatric pyelonephritis.
- More research is required to fully understand the effectiveness and safety profile.
- Current evidence suggests potential benefit, but caution is advised due to reporting limitations.
Background:
Acute pyelonephritis is a common infection in children that may cause renal scarring. The aim of this systematic review and meta-analysis was to analyse the use of corticosteroid treatment to prevent renal scarring.
Methods:
We searched the PubMED, SCOPUS, Cochrane CENTRAL and Web of Science databases in June 2022 for (corticosteroid* or dexamethasone or prednisolone* or prednisone* or hydrocortisone*) AND pyelonephritis. Randomised controlled trials focusing on children were included. The intervention was corticosteroid treatment with antibiotics compared to antibiotics with or without a placebo. The main outcome was the presence of renal scars on dimercaptosuccinic acid scanning at follow-up. The evidence quality was assessed using the GRADE methodology and risk of bias 2.0 tool. We calculated the risk ratio (RR), absolute risk difference (RD) with 95% confidence intervals (CI) and the number needed to treat (NNT). We applied a fixed effects model due to low heterogeneity.
Results:
We screened 872 abstracts and included five full texts. Renal scarring at follow-up was found in 31/220 (14.1%) patients in the corticosteroid groups and 76/278 (27.3%) in the control groups (RR 0.65, CI 0.44-0.96, RD - 13.2%, NNT 8). The evidence quality was moderate. Two studies reported adverse events with no differences between the groups. The risk of bias analysis showed some concerns in four studies.
Conclusion:
We found moderate quality evidence that adjuvant corticosteroid treatment could prevent renal scarring. Adverse events were insufficiently reported, and more research on their effectiveness and harm is therefore needed before using corticosteroids in clinical settings.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Transplant II: Surgical Procedure
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury V: Interprofessional Care
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Nephrotic Syndrome III : Nursing Management

